JSC Pharmstandard, a Russian pharmaceutical industry leader, and Viriom LLC, a company engaged in the development of innovative medicines, signed an agreement on intentions on August 20, 2018.
The parties declared their readiness to start production of the domestic innovative drug ELPIDA® (INN Elsulfavirin) for the treatment of HIV infection at the facilities of Pharmstandard. The project is aimed at increasing the availability of innovative drug therapy, increasing the coverage of patients in accordance with the targets of the HIV 2020 Strategy, and further development of the Russian pharmaceutical industry.
Viriom developed the drug in cooperation with F.Hoffmann-La Roche (Switzerland) with the support of the Ministry of Industry and Trade (within the framework of the Federal Target Program “Pharma 2020”).
ELPIDA® represents a new generation of non-nucleoside HIV reverse transcriptase inhibitors (NNRTI). This is an innovative drug for the treatment of HIV infection with a full cycle production in Russia of both finished dosage form (capsules 20 mg) and a pharmaceutical substance.